Marisa Wexler, MS, senior science writer —

Targeting certain regions of the alpha-synuclein protein could be a viable therapeutic strategy for Parkinson’s disease, a study suggests. The study, “Two C-terminal sequence variations determine differential neurotoxicity between human and mouse α-synuclein,” was published in the journal Molecular Neurodegeneration. Parkinson’s disease is characterized by…

The investigational gene therapy AXO-Lenti-PD continues to be well-tolerated and to ease disease symptoms in people with Parkinson’s, new SUNRISE-PD trial data covering a second and higher dose patient group indicate. Parkinson’s disease is characterized by a gradual loss of the neurons in the brain that make dopamine, a neurotransmitter involved…

Oral Ongentys (opicapone) as a daily add-on treatment shortened overnight “off” periods and eased dyskinesia during “on” periods in people with Parkinson’s disease using levodopa, new analyses of Phase 3 clinical trial data show. Long-term use was also seen to lower patients’ average daily levodopa dose without worsening symptoms…

Ongentys (opicapone) can reduce the extent of “off” periods in people with Parkinson’s disease being treated with  levodopa, new clinical trial data show. The data were presented at the American Neurological Association 2020 Virtual Meeting. Therapies that aim to increase levels of dopamine in the brain,…

Spinal cord stimulation can effectively decrease pain, and also may help alleviate motor symptoms, in people with Parkinson’s disease (PD), regardless of whether patients have previously undergone deep brain stimulation, a small study suggests. The study, “Single arm prospective multicenter case series on the use of…

Cognitive changes in people with Parkinson’s disease pose a substantial challenge for their care partners, new research suggests. The findings were presented at the 2020 Congress of Parkinson’s Disease and Movement Disorders (held virtually due to the COVID-19 pandemic) by researchers from the Parkinson’s Foundation, in…

Supernus Pharmaceuticals has submitted a new drug application to the U.S. Food and Drug Administration (FDA) seeking approval of SPN-830, its apomorphine infusion pump, the company said. If approved, the pump will be used for the continuous treatment of on-off episodes in adults with Parkinson’s…

Sunovion‘s Kynmobi (apomorphine hydrochloride), a sublingual film treatment for “off” episodes in people with Parkinson’s disease, has a manageable safety profile and maintains efficacy over up to nearly a year of use, interim data from an ongoing Phase 3 trial show. Findings were presented at MDS…

Vercise Genus, a fourth-generation system for deep brain stimulation (DBS) made by Boston Scientific, has received CE marking and is now commercially available in Europe. A treatment approach for Parkinson’s disease, DBS involves surgically implanting a neurostimulator to deliver electrical impulses to targeted regions of…

A speech therapy called the Lee Silverman Voice Treatment (LSVT LOUD) can lessen difficulties in communication for people with Parkinson’s disease, a new study shows. The study, “The Impact of Lee Silverman Voice Treatment (LSVT LOUD) on Voice, Communication, and Participation: Findings from a Prospective, Longitudinal…